复宏汉霖/四环/康华/先健/国药随A股同业涨逾8%-10% 前者创上市新高 惟康希诺倒跌7%
内地医药生物/病毒防治、中药、生物疫苗及流感板块逆市升1.9%-4.1%。医药及医疗器械等相关板块也普遍跑赢大市(恒指反覆续升0.4%)，尤其是主要开发及制销心血管和外周血管疾病及紊乱所用先进微创介入医疗器械的先健科技(01302.HK)突破3月所创52周高位2.02元，最高见2.15元，创近两年高现造2.07元，续涨10%，成交急增至6,420万股，为几年罕见，涉资近1.31亿元。
在内地经营私营医院的康华医疗(03689.HK)急弹14%报3.2元，股价重越10天及20天线。
国药(01099.HK)也发力追落後，股价一举升破20天、50天、10天及百天线(19.5-21.07元)，最高见21.8元，现造21元，急弹10.5%，成交急增至3,723万股，为一年来最最多，涉资7.82亿元。四环医药(00460.HK)突破百天线(0.84元)，最高见0.92元，现造0.91元，续涨9.6%，成交续增至8,299万股，涉资7,369万元。
由复星医药(02196.HK)分拆去年9月25日以每股49.6元上市的复宏汉霖-B(02696.HK)突破挂牌第三天盘中所创上市高位50.9元，最高见55.35元，现造54.7元，续升8.3%，成交额2,629万元；其母企复星医药高见27.7元，现造27.6，回升5.1%。
上海医药(02607.HK)四连升，最高见13.7元，接近百天线(13.71元)，现造13.6元，续升逾2%。丽珠医药(01513.HK)四连升屡探顶，最高见37.35元，创两年高，现造36.75元，续升2.8%。白云山(00874.HK)曾一举重越10天及百天线(20.95元及21.85元)，最高见22元，现造21.75元，续升3.6%。
康龙化成(03759.HK)、蓝筹石药(01093.HK)、石四药(02005.HK)、康方生物-B(09926.HK)、康龙化成(03759.HK)、亚盛医药-B(06855.HK)、春立医疗(01858.HK)、华领医药-B(02552.HK)、歌礼制药-B(01672.HK)、华润医药(03320.HK)、东阳光药(01558.HK)、蓝筹中生制药(01177.HK)及绿叶制药(02186.HK)续弹逾2%-4%，後两者最大，分别高见14.68元及高见4.76元，前者为最强蓝筹，後者回补3月9日部分下跌裂口(4.82-4.74元)。
不过，维亚生物(01873.HK)、福森药业(01652.HK)、君实生物医药-B(01877.HK)、复旦张江生物医药(01349.HK)、希玛眼科(03309.HK)、康宁杰瑞制药-B(09966.HK)、中国抗体制药-B(03681.HK)及康希诺生物-B(06185.HK)依次跌1.5%-7%，後者最伤，该股承过去两天升势今早高开升至204.8元乏力，掉头失守20天线(186.4元)，最低见183.1元，现造185.7元，倒跌7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
